Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRYP Therapeutics Inc C.TRYP

Healthcare
Tryp Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Company’s lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The Company's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience.


CSE:TRYP - Post by User

TRYP Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Post by maysilverstoneon Jul 23, 2021 12:20pm
133 Views
Post# 33596315

$TRYP- Psychedelic stock to watch

$TRYP- Psychedelic stock to watch
As the acceptance of psychedelic treatments rapidly increase along with the prevalence of mental disorders, the psychedelic market is expected to grow with a CAGR of 16.3% to reach $6.85B by 2027.
 
A psychedelic company that I'm watching closely is TRYP Therapeutics, a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs.
 
They are working to get their psilocybin treatments approved by the FDA and on the market.
By targeting the 505 b2 and the orphan drug design, $TRYP is granted the "Orphan Drug Status", meaning that they receive

- Much shorter review wait times

- Federal tax credit for clinical trials

- Direct written recommendation from the FDA on the trials
 
They also recently announced plans for a Phase 2a clinical trial to evaluate the efficacy of TRYP-8802 for treating Fibromyalgia with the University of Michigan.
 
I found this video by a big YouTuber that does some good DD on TRYP, check it out: https://www.youtube.com/watch?v=fEJOi4aSjkE

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities